Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Feb 4 (Reuters) - Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...